explore -WSS

explore

author：entertainment 2025-09-30 14:10:14 - browse：97281

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： The battle over 'scope creep' and who gets to be called 'doctor'

WSS

The haunting brain science of long Covid

Is there really a nursing shortage in the U.S.?

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Study on Amgen’s bispecific immunotherapy produces positive data

New lawsuit accuses health insurer Cigna of denying claims in bulk

FDA clears Verve to begin U.S. study of gene

focus

explore

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

CDC Director Mandy Cohen on transparency, trust, and health

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Truvian presents data for its desktop blood

New air purifier tech could be key to improving indoor air quality

How doctors’ personal politics affect patients

Medical records are filled with copy

CDC Director Mandy Cohen on transparency, trust, and health

Sports medicine is finally prioritizing gender equality

Will the FTC rein in IQVIA's health data empire?

focus

Readout LOUD podcast: Live from the 2023 STAT Summit

Device maker Teleflex to acquire urology company for $600M

STAT Summit: The economic case for universal basic health care

Results on Novartis prostate cancer therapy could expand its use

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Is there really a nursing shortage in the U.S.?

hotspot

focus

hotspot

explore